Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Capadenoson. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 known ✓ | P30542 | 20/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3299665 | 0.92 | ADORA1 (0.86) | ADORA1SLC6A3 | |
| SCHEMBL13998935 | 0.92 | ADORA1 (0.85) | ADORA1SLC6A3 | |
| SCHEMBL1932981 | 0.92 | ADORA1 (0.85) | ADORA1SLC6A3 | |
| SCHEMBL20211460 | 0.92 | ADORA1 (0.85) | ADORA1SLC6A3 | |
| SCHEMBL14464879 | 0.91 | ADORA1 (0.84) | ADORA1SLC6A3 | |
| SCHEMBL7972583 | 0.91 | ADORA1 (0.84) | ADORA1SLC6A3 | |
| SCHEMBL1177603 | 0.91 | ADORA1 (0.83) | ADORA1SLC6A3 | |
| SCHEMBL7602052 | 0.91 | ADORA1 (0.83) | ADORA1SLC6A3 | |
| SCHEMBL3697062 | 0.90 | ADORA1 (0.82) | ADORA1SLC6A3 | |
| SCHEMBL14632034 | 0.90 | ADORA1 (0.82) | ADORA1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120114604-A | Application of adenosine and receptor thereof in cardiopulmonary and cerebral resuscitation and multi-organ injury | 中南大学湘雅医院 | 2025-06-10 | — | — | CN | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| WO-2017137528-A1 | ADENOSINE A1 RECEPTOR AGONIST FOR USE IN TREATMENT OF STATUS EPILEPTICUS | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2017-08-17 | — | — | WO | claimed |
| US-20160311812-A1 | ADENOSINE A1 AGONISTS AS MEDICAMENTS FOR KIDNEY DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-27 | — | — | US | claimed |
| WO-2013049725-A2 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2013-04-04 | — | — | WO | claimed |
| US-20080306070-A1 | Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders | BAYER HEALTHCARE AG | 2008-12-11 | — | — | US | claimed |
| EP-1933841-A1 | COMBINATION THERAPY COMPRISING SUBSTITUTED OXAZOLIDINONES FOR THE PREVENTION AND TREATMENT OF CEREBRAL CIRCULATORY DISORDERS | Bayer HealthCare AG (DE) | 2008-06-25 | — | — | EP | claimed |
| WO-2007039134-A1 | COMBINATION THERAPY COMPRISING SUBSTITUTED OXAZOLIDINONES FOR THE PREVENTION AND TREATMENT OF CEREBRAL CIRCULATORY DISORDERS | BAYER HEALTHCARE AG (DE) | 2007-04-12 | — | — | WO | claimed |
| CN-116710439-B | Substituted pyrazolopiperidine carboxylic acids | BAYER AG (DE) | 2026-05-26 | — | — | CN | disclosed |
| CN-116829545-B | Substituted pyrazolylpiperidine carboxylic acids | 拜耳公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260125401-A1 | BORON-CONTAINING RHO KINASE INHIBITORS | PERCIPIAD, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| US-12595247-B2 | Substituted pyrazolo piperidine carboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 2026-04-07 | — | — | US | disclosed |
| US-20250361282-A1 | ATRIAL NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES | BAYER AKTIENGESELLSCHAFT (DE) | 2025-11-27 | — | — | US | disclosed |
| WO-2007039134-A1 | COMBINATION THERAPY COMPRISING SUBSTITUTED OXAZOLIDINONES FOR THE PREVENTION AND TREATMENT OF CEREBRAL CIRCULATORY DISORDERS | BAYER HEALTHCARE AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| US-20060217373-A1 | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same | BAYER HEALTHCARE AG (DE) | 2006-09-28 | — | — | US | disclosed |
| US-7109218-B2 | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same | BAYER HEALTHCARE AG (DE) | 2006-09-19 | — | — | US | disclosed |
| US-20050227972-A1 | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same | BAYER HEALTHCARE AG (DE) | 2005-10-13 | — | — | US | disclosed |
| EP-1455785-A1 | SUBSTITUTED 2-THIO-3,5-DICYANO-4-PHENYL-6-AMINOPYRIDINES AND THE USE OF THE SAME | Bayer HealthCare AG (DE) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003053441-A1 | SUBSTITUTED 2-THIO-3,5-DICYANO-4-PHENYL-6-AMINOPYRIDINES AND THE USE OF THE SAME | BAYER HEALTHCARE AG (DE) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227972-A1 | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same | TPMT, QDPR, TUBB6 | ADORA1 998/4885SLC6A3 215/4885 |
| US-20080306070-A1 | Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders | OTC, SDHA, SDHB | ADORA1 1133/4885SLC6A3 1807/4885 |
| US-20060217373-A1 | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same | TPMT, QDPR, TUBB6 | ADORA1 998/4885SLC6A3 215/4885 |
| US-12595247-B2 | Substituted pyrazolo piperidine carboxylic acids | SSB, PDK4, FPR1 | ADORA1 1029/4885SLC6A3 1384/4885 |
| US-20260125401-A1 | BORON-CONTAINING RHO KINASE INHIBITORS | NTRK2, GRK6, GRK1 | ADORA1 2774/4885SLC6A3 312/4885 |
| US-20160311812-A1 | ADENOSINE A1 AGONISTS AS MEDICAMENTS FOR KIDNEY DISORDERS | ADORA1, ADORA2A, ADORA2B | ADORA1 1/4885SLC6A3 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.